Redefining Immunotherapy
Virometix AG
Incorporated
28.09.2009Headquarters
SchlierenSupport
A new platform technology called Synthetic Virus-Like Particle (SVLP) technology for synthetic vaccine design has been developed. The technology has the potential to revolutionize vaccine design. The aim is to create a start-up company with the goal to further develop and commercialize the SVLP technology.
News
Venture Leaders Biotech 2024: 10 innovative startups selected for the Boston roadshow (venturelab.swiss)
New leaders on the executive floor (startupticker.ch)
Biotech startup Virometix obtains CHF 7.5 M in a series B round (startupticker.ch)
Virometix to kick off in-human studies of its first vaccine candidate (startupticker.ch)
Anna Sumeray takes over from Arin Ghasparian (startupticker.ch)
Virometix closes extension financing round (startupticker.ch)
Virometix closes extension financing round (startupticker.ch)
Virometix Closes Financing Round (startupticker.ch)
Virometix Closes Financing Round (startupticker.ch)
Virometix closes oversubscribed financing round (startupticker.ch)
Virometix closes extension financing round (startupticker.ch)
Gewinner des Awards der W. A. de Vigier Stiftung: Virometix (startupticker.ch)
Sieben Mal 100 000 Franken für Gründer (startupticker.ch)
CTI Start-up Label for Numab, Qvanteq, SwissTV and Virometix (startupticker.ch)